UroGen Pharma URGN
UroGen Pharma Ltd. · Nasdaq · Pharmaceutical Preparations
$33.48-0.80%close on Oct. 29, 2026 · volume 1.4M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 8, 2026 | Chris Degnan Chief Financial Officer | Sold | 2,202 | $36.69 | $80,791 |
| Sept. 8, 2026 | Mark Schoenberg Chief Medical Officer | Sold | 871 | $42.92 | $37,383 |
| Sept. 8, 2026 | Jason Drew Smith General Counsel | Sold | 1,519 | $42.54 | $64,618 |
| Aug. 20, 2026 | Mark Schoenberg Chief Medical Officer | Sold | 60,677 | $47.05 | $2.85 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Other events